Voyager Therapeutics Entered into a License Option Agreement with Novartis to Develop Gene Therapies for the Treatment of Neurological Diseases
- Voyager to receive $54M up front, ~$37.5M in exercise fees for 3 CNS targets, ~$1.5B in milestones for products utilizing Voyager licensed capsids along with royalties. Novartis has option to elect up to 2 additional targets for $18M upon selection for each target & $12.5M in exercise fee for each target
- Novartis gets the target-specific access to Voyager’s TRACER AAV capsids & gets exercise options to license capsids for exclusive use in the development of AAV gene therapies for 3 targets
- Voyager’s TRACER platform helps to deliver therapies to intractable regions of the brain & reduce the barriers that inhibit the gene therapies development for neurological diseases
Ref: Globe Newswire | Image: Voyager
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.